Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672396 | 0.90 | HCRTR1 (0.43) | SLC6A3SLC6A2SLC6A4ENPP2 | |
| SCHEMBL5669924 | 0.83 | POLB (0.43) | SLC6A3SLC6A2SLC6A4FAAHENPP2 | |
| SCHEMBL28757290 | 0.81 | LTA4H (0.41) | SLC6A3SLC6A2SLC6A4ENPP2 | |
| SCHEMBL6750837 | 0.80 | GRM2 (0.45) | ENPP2 | |
| SCHEMBL6750841 | 0.79 | FAAH (0.39) | FAAH | |
| SCHEMBL5406382 | 0.74 | SLC6A3 (0.40) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5398006 | 0.71 | KCNA5 (0.40) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5883779 | 0.70 | PDE6D (0.39) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6750843 | 0.69 | FAAH (0.45) | FAAH | |
| SCHEMBL5672388 | 0.68 | LTA4H (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO-CELTIQUE S.A. | 2004-05-20 | — | — | US | claimed |
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO-CELTIQUE S.A. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | SCN1A, CACNA1S, SCN1B | SLC6A3 94/4885SLC6A2 79/4885SLC6A4 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.